IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol

Petra Dörge; Barbara Meissner; Martin Zimmermann; Anja Möricke; André Schrauder; Jean-Pierre Bouquin; Denis Schewe; Jochen Harbott; Andrea Teigler-Schlegel; Richard Ratei; Wolf-Dieter Ludwig; Rolf Koehler; Claus R. Bartram; Martin Schrappe; Martin Stanulla; Gunnar Cario

doi:10.3324/haematol.2011.056135

Haematologica (Mar 2013)

IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol

Petra Dörge,
Barbara Meissner,
Martin Zimmermann,
Anja Möricke,
André Schrauder,
Jean-Pierre Bouquin,
Denis Schewe,
Jochen Harbott,
Andrea Teigler-Schlegel,
Richard Ratei,
Wolf-Dieter Ludwig,
Rolf Koehler,
Claus R. Bartram,
Martin Schrappe,
Martin Stanulla,
Gunnar Cario

Affiliations

Petra Dörge: Department of Pediatrics, University Medical Centre Schleswig-Holstein, Kiel, Germany;
Barbara Meissner: Department of Pediatrics, University Medical Centre Schleswig-Holstein, Kiel, Germany;
Martin Zimmermann: Department of Pediatric Hematology and Oncology, Hannover Medical School, Germany;
Anja Möricke: Department of Pediatrics, University Medical Centre Schleswig-Holstein, Kiel, Germany;
André Schrauder: Department of Pediatrics, University Medical Centre Schleswig-Holstein, Kiel, Germany;
Jean-Pierre Bouquin: Division of Pediatric Oncology, University Children’s Hospital Zurich, Switzerland;
Denis Schewe: Department of Pediatrics, University Medical Centre Schleswig-Holstein, Kiel, Germany;
Jochen Harbott: Department of Pediatric Hematology and Oncology, University Hospital Giessen and Marburg, Giessen, Germany;
Andrea Teigler-Schlegel: Department of Pediatric Hematology and Oncology, University Hospital Giessen and Marburg, Giessen, Germany;
Richard Ratei: Department of Hematology, Oncology and Tumor Immunology, HELIOS-Clinic Berlin-Buch, Berlin, Germany;
Wolf-Dieter Ludwig: Department of Hematology, Oncology and Tumor Immunology, HELIOS-Clinic Berlin-Buch, Berlin, Germany;
Rolf Koehler: Department of Human Genetics, University of Heidelberg, Heidelberg, Germany
Claus R. Bartram: Department of Human Genetics, University of Heidelberg, Heidelberg, Germany
Martin Schrappe: Department of Pediatrics, University Medical Centre Schleswig-Holstein, Kiel, Germany;
Martin Stanulla: Department of Pediatrics, University Medical Centre Schleswig-Holstein, Kiel, Germany;
Gunnar Cario: Department of Pediatrics, University Medical Centre Schleswig-Holstein, Kiel, Germany;

DOI: https://doi.org/10.3324/haematol.2011.056135
Journal volume & issue: Vol. 98, no. 3

Abstract

Read online

IKZF1 gene deletions have been associated with a poor outcome in pediatric precursor B-cell acute lymphoblastic leukemia. To assess the prognostic relevance of IKZF1 deletions for patients treated on Berlin-Frankfurt-Münster Study Group trial ALL-BFM 2000, we screened 694 diagnostic acute lymphoblastic leukemia samples by Multiplex Ligation-dependent Probe Amplification. Patients whose leukemic cells bore IKZF1 deletions had a lower 5-year event-free survival (0.69±0.05 vs. 0.85±0.01; P

Published in Haematologica

ISSN: 0390-6078 (Print); 1592-8721 (Online)
Publisher: Ferrata Storti Foundation
Country of publisher: Italy
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Diseases of the blood and blood-forming organs
Website: http://www.haematologica.org

About the journal